文献速递系统性红斑狼疮

皮下注射贝利木单抗治疗系统性红斑狼疮的52周随机双盲安慰剂对照研究

Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study.
PubMed 文献 · Arthritis Rheumatol · 2017-04-07

该研究纳入839例中重度系统性红斑狼疮(SLE)患者,按2:1随机接受每周皮下注射贝利木单抗200mg或安慰剂,联合标准治疗52周。主要终点第52周SRI4应答率贝利木单抗组61.4%高于安慰剂组48.4%(OR 1.68,95%CI 1.25-2.25,P=0.0006),且严重复发风险降低,安全性两组相当。

要点

  • 皮下贝利木单抗200mg每周一次联合标准治疗显著提高SLE患者SRI4应答率。
  • 贝利木单抗组严重复发时间延长、风险降低(HR 0.51,95%CI 0.35-0.74)。
  • 不良事件发生率与安慰剂组相当,严重不良事件贝利木单抗组10.8%、安慰剂组15.7%。

核心结论

  • 中重度SLE患者每周皮下注射贝利木单抗200mg联合标准治疗,可显著改善SRI4应答并减少严重复发,安全性类似安慰剂联合标准治疗。

研究设计与样本

  • 52周随机、双盲、安慰剂对照研究,839例中重度SLE患者按2:1随机接受每周皮下贝利木单抗200mg或安慰剂,联合标准SLE治疗。
  • 入组患者SELENA-SLEDAI评分≥8,贝利木单抗组平均10.5分,安慰剂组平均10.3分。

主要发现

  • 第52周SRI4应答率贝利木单抗组61.4% vs 安慰剂组48.4%(OR 1.68,95%CI 1.25-2.25,P=0.0006)。
  • 严重复发中位时间贝利木单抗组171.0天 vs 安慰剂组118.0天(HR 0.51,95%CI 0.35-0.74,P=0.0004)。
  • 第40-52周激素剂量降低≥25%(至≤7.5mg/天)的患者比例贝利木单抗组18.2% vs 安慰剂组11.9%(OR 1.65,95%CI 0.95-2.84,P=0.0732)。
  • 严重不良事件发生率贝利木单抗组10.8% vs 安慰剂组15.7%;IgG低球蛋白血症恶化≥2级发生率贝利木单抗组0.9% vs 安慰剂组1.4%。

关键数值与推荐

  • 主要终点为第52周SRI4应答率。
  • 次要终点包括激素剂量降低和严重复发时间。

临床怎么用

  • 对于中重度SLE患者,可考虑每周皮下注射贝利木单抗200mg联合标准治疗以改善应答并减少严重复发。
  • 治疗期间需监测不良事件,尤其是严重不良事件和IgG低球蛋白血症变化。

局限性

  • 159例患者在研究结束前退出。
  • 激素剂量降低≥25%的组间差异未达到统计学显著性(P=0.0732)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the efficacy and safety of subcutaneous (SC) belimumab in patients with systemic lupus erythematosus (SLE). METHODS: Patients with moderate-to-severe SLE (score of ≥8 on the Safety of Estrogens in Lupus Erythematosus National Assessment [SELENA] version of the SLE Disease Activity Index [SLEDAI]) were randomized 2:1 to receive weekly SC belimumab 200 mg or placebo by prefilled syringe in addition to standard SLE therapy for 52 weeks. The primary end point was the SLE Responder Index (SRI4) at week 52. Secondary end points were reduction in the corticosteroid dosage and time to severe flare. Safety was assessed according to the adverse events (AEs) reported and the laboratory test results. RESULTS: Of 839 patients randomized, 836 (556 in the belimumab group and 280 in the placebo group) received treatment. A total of 159 patients withdrew before the end of the study. At entry, mean SELENA-SLEDAI scores were 10.5 in the belimumab group and 10.3 in the placebo group. More patients who received belimumab were SRI4 responders than those who received placebo (61.4% versus 48.4%; odds ratio [OR] 1.68 [95% confidence interval (95% CI) 1.25-2.25]; P = 0.0006). In the belimumab group, both time to and risk of severe flare were improved (median 171.0 days versus 118.0 days; hazard ratio 0.51 [95% CI 0.35-0.74]; P = 0.0004), and more patients were able to reduce their corticosteroid dosage by ≥25% (to ≤7.5 mg/day) during weeks 40-52 (18.2% versus 11.9%; OR 1.65 [95% CI 0.95-2.84]; P = 0.0732), compared with placebo. AE incidence was comparable between treatment groups; serious AEs were reported by 10.8% of patients taking belimumab and 15.7% of those taking placebo. A worsening of IgG hypoglobulinemia by ≥2 grades occurred in 0.9% of patients taking belimumab and 1.4% of those taking placebo. CONCLUSION: In patients with moderate-to-severe SLE, weekly SC doses of belimumab 200 mg plus standard SLE therapy significantly improved their SRI4 response, decreased severe disease flares as compared with placebo, and had a safety profile similar to placebo plus standard SLE therapy.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Stohl W, Schwarting A, Okada M, et al. Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study. Arthritis Rheumatol. 2017. PMID: 28118533. doi:10.1002/art.40049

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。